US 11,752,205 B1
Compositions and methods of enhancing immune responses
Sherryll Layton, Lisbon, NH (US); and Jeffrey W. Hall, Minneapolis, MN (US)
Filed by Sherryll Layton, Lisbon, NH (US); and Jeffrey W. Hall, Minneapolis, MN (US)
Filed on Sep. 20, 2022, as Appl. No. 17/933,516.
Application 17/933,516 is a division of application No. 17/180,012, filed on Feb. 19, 2021, granted, now 11,497,801.
Int. Cl. C12Q 1/68 (2018.01); A61K 39/015 (2006.01); A61K 39/012 (2006.01); A61K 39/39 (2006.01); A61P 33/02 (2006.01); A61K 39/002 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/015 (2013.01) [A61K 39/002 (2013.01); A61K 39/012 (2013.01); A61K 39/39 (2013.01); A61P 33/02 (2018.01); A61K 2039/523 (2013.01)] 6 Claims
 
1. A vaccine vector comprising:
a polynucleotide encoding the antigenic polypeptide selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, or any combination thereof.